Abstract
Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Current Pharmaceutical Design
Title:How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Volume: 19 Issue: 21
Author(s): Vasilios Tsimihodimos, Matilda Florentin and Moses S. Elisaf
Affiliation:
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Abstract: Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Export Options
About this article
Cite this article as:
Tsimihodimos Vasilios, Florentin Matilda and S. Elisaf Moses, How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/ 10.2174/13816128113199990304
DOI https://dx.doi.org/ 10.2174/13816128113199990304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry Editorial (Hot Topic: Blood Pressure Diseases in Chronic Kidney Disease: An Old Totem or A New Vision)
Current Hypertension Reviews Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
Current Pharmaceutical Design Acute Coronary Syndromes: A Role of Immune System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics
Current HIV Research Endothelial Dysfunction and Coronary Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Lessons from the REACH Registry in Europe
Current Vascular Pharmacology Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Ox-LDL and LOX-1 in Atherogenesis
Current Medicinal Chemistry Home Blood Pressure-guided Anticipation Management of Hypertension: Effective to the Gap Between the Guidelines and the Individualized Medicine
Current Hypertension Reviews Endothelial to Mesenchymal Transition in the Cardiogenesis and Cardiovascular Diseases
Current Cardiology Reviews Clinical Applications of Non-Antimicrobial Actions of Tetracyclines in Inflammatory Diseases
Current Drug Therapy Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Integration and Querying of Heterogeneous Omics Semantic Annotations for Biomedical and Biomolecular Knowledge Discovery
Current Bioinformatics Amiodarone-Induced SIADH: Two Cases Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin D Deficiency and Acute Lung Injury
Inflammation & Allergy - Drug Targets (Discontinued)